ArticleJournal of physiology and biochemistry2026
Prognostic implications and molecular mechanisms of derived organoid-angiogenesis-related genes (DOARGs) in colorectal cancer.
Article in Journal of physiology and biochemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
This research seeks to investigate the prognostic significance and molecular mechanisms of derived organoid-angiogenesis-related genes (DOARGs) in colorectal cancer (CRC). DOARGs associated with CRC prognosis were screened based on The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) databases. Machine learning techniques were employed to create and assess a signature based on DOARGs, and a nomogram was constructed. Additionally, assessments were conducted on the levels of tumor mutational burden (TMB), immune infiltration, potential chemotherapeutic agents, and immune therapy responses to assess variations between groups with varying risk levels. In vitro experiments, including quantitative reverse-transcription polymerase chain reaction (qRT-PCR), Western blot, CCK-8, and transwell assays were conducted to verify the expression and molecular mechanisms of the model genes. A total of 13 DOARGs significantly associated with prognosis were identified. Five model genes (tissue inhibitor of metalloproteinases 1 (TIMP1), matrix metalloproteinase-1 (MMP1), C-C motif chemokine ligand 24 (CCL24), melanotransferrin (MELTF), and lymphoid enhancer-binding factor 1 (LEF1)) were identified for prognostic signature establishment. This signature demonstrated robust predictive performance for CRC prognosis upon validation. Significant differences were observed in TMB, immune infiltration, potential chemotherapeutic responses, and immune therapy reactions between groups with varying risk levels. Subgroup analysis categorized tumor samples into C1 and C2 groups, with C1 exhibiting significantly lower survival rates compared to C2. qRT-PCR analysis indicated a marked upregulation in the expression of the five model genes in CRC cells, and low expression of CCL24 suppressed the biological functions of CRC cells. This study has developed a prognostic signature for CRC utilizing DOARGs. This signature offers novel targets for the prognosis and personalized treatment of CRC.
Indexed as
Identifiers
41854974What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.